Loqtorzi (toripalimab-tpzi) sold under the brand name 拓益 in china, is a next generation anti-PD-1 monoclonal antibody that blocks PD-L1 binding to the PD-1 receptor at a unique site with high affinity and activates antitumor immunity demonstrating improvement in the overall survival of cancer patients in several tumor types.
Chinese Version
Brand name：Loqtorzi (拓益，ZYTORVI®)
INN name：Toripalimab (特瑞普利单抗)
Manufacturer：Junshi Biosciences (君实生物)
Packaging：240mg*6ml/Box
Inquire&E-mail: care@100pei.com
On October 27, 2023, The FDA approved toripalimab-tpzi (LOQTORZ, Coherus BioSciences, Inc.) with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma (NPC).FDA also approved toripalimab-tpzi as a single agent for adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.
扫一扫 
